CBDV: A Cannabinoid Being Studied for Neurological Conditions
A plain-language look at cannabidivarin and the research so far.
Cannabidivarin, or CBDV, is a non-psychoactive cannabinoid found in cannabis. Structurally it's closely related to CBD — the main difference is a shorter side chain on the molecule — and it won't produce a “high.” CBDV has drawn growing research interest for its possible therapeutic role in neurological conditions, particularly epilepsy and autism spectrum disorder. It's worth saying clearly up front: CBDV research is still at an early stage, and much of what we know comes from laboratory and animal studies rather than large human trials.
Epilepsy and Seizure Research
The most established area of CBDV research is its anticonvulsant (anti-seizure) potential. A frequently cited 2012 study by Hill and colleagues, published in the British Journal of Pharmacology, investigated CBDV's effects in laboratory and rodent models of epilepsy. The researchers found that CBDV acted as an effective anticonvulsant across a broad range of seizure models, and notably did so without significantly affecting normal motor function — leading them to conclude it merited further investigation as a potential anti-epileptic. These were preclinical findings, so they point to promise rather than proof in humans, but they helped establish CBDV as a serious research candidate.
Autism Spectrum Disorder
Because of its effects on brain signaling, CBDV has also been studied in the context of autism spectrum disorder (ASD). One line of research has focused on how CBDV influences the brain's excitatory and inhibitory chemical systems — specifically glutamate and GABA — which are thought to be involved in ASD. A 2019 brain-imaging study at King's College London, for example, examined whether a single dose of CBDV shifts these chemical markers in autistic and non-autistic adults.
CBDV has been the subject of clinical trials exploring whether it can help with symptoms associated with autism, such as irritability and challenging behaviors. As with any developing research area, individual trials start, finish, and sometimes stop early, so the most accurate thing to say is that autism remains an active area of CBDV investigation — with results still emerging and no CBDV-based treatment currently approved for ASD.
Where the Research Goes From Here
Human research on CBDV is still limited compared to better-known cannabinoids like CBD. Ongoing and future studies — in epilepsy, autism, and potentially other neurological and inflammatory conditions — will be needed to clarify how safe and effective CBDV really is, and for whom. For now, CBDV is best understood as a promising cannabinoid worth watching, not an established treatment. Anyone considering cannabinoid-based options for a neurological condition should do so in partnership with a qualified clinician.
Want to understand the cannabinoid family and what the research supports?
Our pharmacist can help you make sense of CBDV, CBD, and other cannabinoids — what's established, what's still being studied, and what it means for your situation. It's a straightforward, no-pressure conversation.
Key references: Hill AJ, et al. Cannabidivarin is
anticonvulsant in mouse and rat. British Journal of Pharmacology,
2012;167(8):1629–1642. Pretzsch CM, et al. Effects of
cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with
and without Autism Spectrum Disorder. Translational Psychiatry, 2019.
This article is for general information only and is not medical advice. The
research on CBDV is largely preclinical or early-stage, and findings may not
translate directly into approved treatments. Please consult a qualified
healthcare professional before making any treatment decisions.